FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine.
On September 27, 1996, the Food and Drug Administration (FDA) licensed a Haemophilus b Conjugate Vaccine (ActHIB) combined by reconstitution with diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (Tripedia) for use as the fourth dose in the childhood vaccination series. This combination vaccine will be sold under the trade name TriHIBit. On July 31, 1996, Tripedia was licensed for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series. TriHIBit is the first vaccine to be licensed in the United States that combines DTaP with a Haemophilus b Conjugate Vaccine.
D002648:Child; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology; D017277:Drug Approval; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D013745:Tetanus Toxoid / Q000008:administration & dosage; D014481:United States; D014486:United States Food and Drug Administration; D018074:Vaccines, Conjugate / Q000008:administration & dosage
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; C055753:Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate; C080881:diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine